According to a study by Coherent market Insights, and is expected to grow at a CAGR of 11.3% in terms of revenue over the forecast period (2024-2031). Mr. Shah Coherent Market Insights Pvt. Ltd. +1 ...
Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback